Skip to content
CheckOrphan
  • Home
  • About Us
  • Log In
  • News
    • All News
    • Finance
    • Treatment
    • People
    • Research
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • About Access Programs
  • Diseases
  • Events
  • Networks
  • Research
Main Menu

Subscribe for Free Newsletter

Email *

Type *

* Required Field
Email Marketing Services by Benchmark

Generate RSS

  1. Home
  2. /
  3. Clinical Trial
  4. /
  5. Sintilimab in Combination With...

Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL

April 10, 2021checkorphan
Learn more about:
Angioimmunoblastic T-Cell Lymphoma
Related Clinical Trial
Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies

Recruitment Information

Administrative Informations

Related News

  • FDA Grants RMAT Designation to March Biosciences’ MB-105 CAR-T Thera
  • SELLAS’ SLS009 Receives FDA Orphan Drug Designation for the Trea
  • Sam Neill’s Rare Lymphoma
More News

Related Clinical Trial

  • Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory
  • Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell M
More Clinical Trial

Related

  • FDA Grants RMAT Designation to March Biosciences’ MB-105 CAR-T Thera
  • SELLAS’ SLS009 Receives FDA Orphan Drug Designation for the Trea
  • Sam Neill’s Rare Lymphoma
  • Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory
  • Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell M
  • MitoAction
  • Angioimmunoblastic T-Cell Lymphoma
  • International Patient Organization for Primary Immunodeficiencies
  • Immune Deficiency Foundation
More
pw

About CheckOrphan

CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity.
Click here to know more About Us

Your email is important to us

Each email is sent to a CheckOrphan staff member and will be answered. We only use a contact form to avoid spam.

    Copyright © 2025 CheckOrphan.
    Developed by: Gonza.io logo Developed by: WebOptimalSolutions Powered by: Cloudscale logo